Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia

References

• Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia IRIS 6-year follow-up. Leukemia 2009;23:1054–1061.
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984;63:789–799.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell models. Blood 2003;101:2368–2373.
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–3745.
   PubMed Web of Science ®Google Scholar
• Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18:401–408.
   PubMed Web of Science ®Google Scholar
• Widmer N, Rumpold H, Untergasser G, Feyet A, Buclin T, Decosterd LA. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia 2007;21:1561–1562.
   PubMed Web of Science ®Google Scholar
• Galimberti S, Cervetti G, Guerrini F, et al. Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during imatinib treatment. Cancer Genet Cytogenet 2005;162:57–62.
   PubMed Web of Science ®Google Scholar
• Dulucq S, Bouchet S, Turcq, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024–2027.
   PubMed Web of Science ®Google Scholar
• Kim DH, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res 2009;15:4750–4758.
   PubMed Web of Science ®Google Scholar
• Hatziieremia S, Jordanides NE, Holyoake TL, Mountford JC, Jorgensen HG. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009;37:692–700.
   PubMed Web of Science ®Google Scholar
• Burger H, van Tol H, Boersma AWM, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004;104:2940–2942.
   PubMed Web of Science ®Google Scholar
• Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC. Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006;108:1370–1373.
   PubMed Web of Science ®Google Scholar
• Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 2008;112:3348–3354.
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Saunders V, Hewett D, et al. Dasatinb cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res 2008;14:3881–3888.
   PubMed Web of Science ®Google Scholar
• Engler JR, Frede A, Saunders VA, Zannettino ACW, Hughes TP, White DL. Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 2010;24:765–770.
   PubMed Web of Science ®Google Scholar
• White VA, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064–4072.
   PubMed Web of Science ®Google Scholar
• White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761–2767.
   PubMed Web of Science ®Google Scholar
• Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myloid leukemia. Clin Pharmacol Ther 2008;83:258–264.
   PubMed Web of Science ®Google Scholar
• White D, Saunders V, Lyons AB, et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood 2005;106:2520–2526.
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496–3499.
   PubMed Web of Science ®Google Scholar
• Osborn MP, White DL, Saunders VA, et al. Early dose-escalation in chronic myeloid leukaemia patients with low plasma imatinib levels leads to equivalent BCR-ABL values and drug levels at 6 months to those with optimal drug levels: first analysis from the TIDEL II trial of de-novo patient treated with 600mg imatinib. Blood 2009;114(Suppl. 1): Abstract 1131.
   Web of Science ®Google Scholar
• White D, Saunders V, Grigg A, et al. Measurement of in vivo bcr-abl kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol 2007;25:4445–4451.
   PubMed Web of Science ®Google Scholar
• Schultheis B, Szydlo R, Mahon FX, Apperley JF, Melo JV. Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment. Blood 2005;105:4893–4895.
   PubMed Web of Science ®Google Scholar
• La Rosee P, Holm-Eriksen S, Konig H, et al. Phospho-CRKL monitoring for the assessment of bcr-abl activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib. Haematologica 2008;93:765–769.
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
   PubMed Web of Science ®Google Scholar
• Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of bcr-abl kinase domain mutations in imatinib-naïve patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128–2137.
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al. Abl mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005;23:4100–4109.
   PubMed Web of Science ®Google Scholar
• Ernst T, Erben P, Muller MC, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008;93:186–192.
   PubMed Web of Science ®Google Scholar
• Huntly BJP, Reid AG, Bench AJ. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98:1732–1738.
   PubMed Web of Science ®Google Scholar
• Kreil S, Pfirrmann M, Haferlach C, et al. Heterogeneous prognostic impact of derivative chromosome 9 deletions in chronic myelogenous leukemia. Blood 2007;110:1283–1290.
   PubMed Web of Science ®Google Scholar
• Huntly BJP, Reid AG, Vassiliou G, et al. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. Blood 2003;102:2205–2212.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Talpaz M, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood 2005;105:2281–2286.
   PubMed Web of Science ®Google Scholar
• Castagnetti F, Testoni N, Luatti S, et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol 2010;28:2748–2754.
   PubMed Web of Science ®Google Scholar
• Lange T, Gunther C, Kohler T, et al. High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. Blood 2003;101:2152–2155.
   PubMed Web of Science ®Google Scholar
• Mohty M, Yong ASM, Szydlo RM, Apperley JF, Melo JV. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 2007;110:380–383.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Messa G, Gottardi E, et al. Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer 2004;101:979–988.
   PubMed Web of Science ®Google Scholar
• Crossman LC, Mori M, Hsieh Y, et al. In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica 2005;90:459–464.
   PubMed Web of Science ®Google Scholar
• Frank O, Brors B, Fabarius A, et al. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients. Leukemia 2006;20:1400–1407.
   PubMed Web of Science ®Google Scholar
• Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006;103:2794–2799.
   PubMed Web of Science ®Google Scholar
• Oehler VG, Yeung KY, Choi YE, Bumgarner RE, Raftery AE, Radich JP. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 2009;114:3292–3298.
   PubMed Web of Science ®Google Scholar
• Brazma D, Grace C, Howard J, et al. Genomic profile of chronic myelogenous leukemia: imbalances associated with disease progression. Genes Chromosomes Cancer 2007;46:1039–1050.
   PubMed Web of Science ®Google Scholar
• McWeeney SK, Pemberton LC, Loriaux MM, et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010;115:315–325.
   PubMed Web of Science ®Google Scholar
• Yong ASM, Szydlo RM, Goldman JM. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006;107:205–212.
   PubMed Web of Science ®Google Scholar
• Zheng C, Li L, Haak M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006;20:1028–1034.
   PubMed Web of Science ®Google Scholar